BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 26648320)

  • 21. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
    Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
    Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes].
    Shi J; Shao ZH; Liu H; Jia HR; Sun J; Bai J; Wu YH; Jing LP; He GS; Cao YR; Wang XL; Tu MF; Hao YS; Yang TY
    Zhonghua Xue Ye Xue Za Zhi; 2004 Nov; 25(11):641-4. PubMed ID: 15634564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia.
    Alcasid M; Ma L; Gotlib JR; Arber DA; Ohgami RS
    Int J Lab Hematol; 2017 Apr; 39(2):129-136. PubMed ID: 28133918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Abnormalities of CD34+ cells differentiation and bone marrow cell cycle in myelodysplastic syndrome].
    Li LJ; Fu R; Shao ZH; Wang HQ; Yue LZ; Ruan EB; Liu H; Wang J; Wang HL
    Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):963-6. PubMed ID: 21211213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome.
    Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Guo R; Tierens A; Minden MD; Chang H
    Hum Pathol; 2020 Oct; 104():117-126. PubMed ID: 32798550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of changes in lymphocyte subsets at diagnosis in acute myeloid leukemia on prognosis: association with complete remission rates and relapse free survivals.
    Park SH; Bae MH; Park CJ; Cho YU; Jang S; Lee JH; Lee KH
    J Hematop; 2023 Jun; 16(2):73-84. PubMed ID: 38175440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of the subsets of lymphocytes and their activated status in patients with myelodysplastic syndrome].
    Yang J; Wang C; Xie KC; Yan SK; Gao YR; Cai Q; Qin YW; Wan LP; Cai Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):708-13. PubMed ID: 16928305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Subtype and Functional Biomarker Changes of NK Cells in Peripheral Blood of Patients with Myelodysplastic Syndrome].
    Xu SJ; Shao ZH; Fu R; Wang HQ; Liu H; Liu CY; Zhang W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):832-836. PubMed ID: 28641645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation.
    Pascal V; Brunet C; Pradel V; Thirion X; Andre P; Faucher C; Sampol J; Dignat-George F; Blaise D; Vivier E; Chabannon C
    Leukemia; 2002 Nov; 16(11):2259-66. PubMed ID: 12399971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
    Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
    Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
    Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.
    Chretien AS; Devillier R; Granjeaud S; Cordier C; Demerle C; Salem N; Wlosik J; Orlanducci F; Gorvel L; Fattori S; Hospital MA; Pakradouni J; Gregori E; Paul M; Rochigneux P; Pagliardini T; Morey M; Fauriat C; Dulphy N; Toubert A; Luche H; Malissen M; Blaise D; Nunès JA; Vey N; Olive D
    Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34050021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
    Miesner M; Haferlach C; Bacher U; Weiss T; Macijewski K; Kohlmann A; Klein HU; Dugas M; Kern W; Schnittger S; Haferlach T
    Blood; 2010 Oct; 116(15):2742-51. PubMed ID: 20581309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural killer cell subsets and natural killer-like T-cell populations in benign and neoplastic B-cell proliferations vary based on clinicopathologic features.
    Gibson SE; Swerdlow SH; Felgar RE
    Hum Pathol; 2011 May; 42(5):679-87. PubMed ID: 21292303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Morphological comparison of dysplastic changes between de novo acute myeloid leukemia (AML) with trilineage myelodysplasia and AML developed from de novo myelodysplastic syndromes.
    Kuriyama K; Miyazaki Y; Arimura K; Nagai K; Nakamura H; Matsuo T; Tomonaga M
    Leuk Res; 1995 Feb; 19(2):121-5. PubMed ID: 7869740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH
    BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone marrow mesenchymal stem cells regulate the dysfunction of NK cells via the T cell immunoglobulin and ITIM domain in patients with myelodysplastic syndromes.
    Liu Z; Guo Y; Huang L; Jia Y; Liu H; Peng F; Duan L; Zhang H; Fu R
    Cell Commun Signal; 2022 Oct; 20(1):169. PubMed ID: 36303184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.
    Kremser A; Dressig J; Grabrucker C; Liepert A; Kroell T; Scholl N; Schmid C; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer H
    J Immunother; 2010; 33(2):185-99. PubMed ID: 20139775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.